Physician profile
Paula Silverman
NPI 1265452825
$234.94
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $40.82.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $45.31 | 2019-2020 | |
| Lilly USA, LLC | $27.48 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $26.50 | 2019 | |
| Amgen INC. | $25.37 | 2019 | |
| Astellas Pharma US INC | $22.73 | 2019 | |
| Tesaro, INC. | $18.12 | 2019 | |
| Pfizer INC. | $15.92 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $14.40 | 2020 | |
| Eisai INC. | $14.22 | 2019 | |
| Emd Serono, INC. | $12.97 | 2019 | |
| Genentech USA, INC. | $11.92 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Research and ownership
$2,260.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.